{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:20:24Z","timestamp":1761765624278},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.coph.2012.12.005","type":"journal-article","created":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T16:16:59Z","timestamp":1358266619000},"page":"294-300","source":"Crossref","is-referenced-by-count":14,"title":["Novel anticoagulants in the therapy of peripheral arterial and coronary artery disease"],"prefix":"10.1016","volume":"13","author":[{"given":"Vincenzo","family":"Jacomella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natascia","family":"Corti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Husmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2012.12.005_sbref0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00392-009-0754-1","article-title":"Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort","volume":"98","author":"Zeymer","year":"2009","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.coph.2012.12.005_bib0010","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1331\/154434504322904596","article-title":"Peripheral arterial disease: pathophysiology, risk factors, and role of antithrombotic therapy","volume":"44","author":"Bradberry","year":"2004","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.coph.2012.12.005_bib0015","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2006.03.067","article-title":"The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials","volume":"48","author":"Saw","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2012.12.005_bib0020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","author":"Bhatt","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2012.12.005_sbref0025","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejvs.2011.09.016","article-title":"Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease","volume":"43","author":"Smolderen","year":"2012","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.coph.2012.12.005_bib0030","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.12.005_bib0035","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1161\/CIRCULATIONAHA.108.833665","volume":"119","author":"Morrow","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2012.12.005_sbref0040","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","author":"Anand","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.12.005_bib0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJMe078106","article-title":"Atherothrombosis\u2014wave goodbye to combined anticoagulation and antiplatelet therapy?","volume":"357","author":"Mohler","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.12.005_bib0050","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.12.005_bib0055","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(99)07199-8","article-title":"Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2012.12.005_bib0060","doi-asserted-by":"crossref","first-page":"e669S","DOI":"10.1378\/chest.11-2307","article-title":"Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Alonso-Coello","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.coph.2012.12.005_sbref0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1160\/TH09-05-0327","article-title":"New oral anticoagulant drugs in cardiovascular disease","volume":"104","author":"Ahrens","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coph.2012.12.005_bib0070","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000083809","article-title":"Angiogenesis: a link to thrombosis in athero-thrombotic disease","volume":"33","author":"Conway","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.coph.2012.12.005_bib0075","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11883-012-0269-5","article-title":"Role of tissue factor in atherothrombosis","volume":"14","author":"Owens","year":"2012","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.coph.2012.12.005_bib0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1373\/clinchem.2007.097360","article-title":"Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction","volume":"54","author":"Packard","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.coph.2012.12.005_bib0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11010-011-1024-x","article-title":"Thrombin and vascular inflammation","volume":"359","author":"Popovic","year":"2012","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.coph.2012.12.005_sbref0090","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/j.1538-7836.2012.04782.x","article-title":"The impact of blood coagulability on atherosclerosis and cardiovascular disease","volume":"10","author":"Loeffen","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coph.2012.12.005_sbref0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.12.005_bib0100","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.coph.2012.12.005_bib0105","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/CIRCULATIONAHA.112.115410","article-title":"Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature","volume":"126","author":"Dentali","year":"2012","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.coph.2012.12.005_bib0110","doi-asserted-by":"crossref","first-page":"e001592","DOI":"10.1136\/bmjopen-2012-001592","article-title":"Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials","volume":"2","author":"Mak","year":"2012","journal-title":"BMJ Open"},{"issue":"Suppl 2","key":"10.1016\/j.coph.2012.12.005_bib0115","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.thromres.2012.02.028","article-title":"Tissue factor-driven thrombin generation and inflammation in atherosclerosis","volume":"129","author":"ten Cate","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.coph.2012.12.005_bib0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1472-8206.2011.00981.x","article-title":"Pharmacodynamic and pharmacokinetic basics of rivaroxaban","volume":"26","author":"Kreutz","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.coph.2012.12.005_bib0125","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2174\/138945012800564059","article-title":"Apixaban: a new player in the anticoagulant class","volume":"13","author":"Agrawal","year":"2012","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.coph.2012.12.005_bib0130","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","article-title":"Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies","volume":"6","author":"Wong","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coph.2012.12.005_bib0135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/ejh.12002","article-title":"Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study","volume":"89","author":"Prandoni","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.coph.2012.12.005_bib0140","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Buller","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.12.005_bib0145","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/erc.11.62","article-title":"Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study)","volume":"9","author":"Romualdi","year":"2011","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.coph.2012.12.005_sbref0150","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.12.005_bib0155","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2012.12.005_bib0160","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2012.02.008","article-title":"New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper","volume":"59","author":"De Caterina","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2012.12.005_bib0165","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials","volume":"172","author":"Uchino","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.coph.2012.12.005_bib0170","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","article-title":"RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489212002421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489212002421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T14:01:26Z","timestamp":1539957686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489212002421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1471489212002421"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2012.12.005","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}